Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Individuals with chronic genotype 3 HCV infection and compensated cirrhosis~* Individuals with or without HIV-1 coinfection~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment assessment or compliance with the protocol~* Co-infection with active hepatitis B virus~* Laboratory results outside the acceptable ranges at screening~* Pregnant or nursing female~* Chronic liver disease not caused by HCV~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks
- SOF/VEL + RBV (Type: EXPERIMENTAL): SOF/VEL FDC + RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).